Sequenom, SensiGen in diagnostics alliance
This article was originally published in Clinica
Molecular diagnostic specialist Sequenom has agreed to collaborate with biotechnology company SensiGen to develop and commercialise the latter's AttoSense tests. Sequenom will look to integrate Sensigen's assays into its own quantitative gene expression technology and its MassARRAY DNA analysis technology, for detecting diseases including cervical cancer, chronic kidney disease, inflammatory bowel disease and lupus.
You may also be interested in...
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.
Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved drugs will become available under ruling against HHS; co-plaintiff sought eteplirsen study data.